Jazz Pharmaceuticals (JAZZ) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary

Key product and pipeline updates

• Zanidatamab received approval in second-line BTC and is progressing toward potential approval in frontline GEA, with a PDUFA date of August 25th and breakthrough designation in the U.S.

• Expansion efforts include trials in later-line breast cancer post-ENHERTU, with accrual expected to complete mid-2025 and results as early as late 2027.

• A basket trial for zanidatamab is underway, aiming for a tumor-agnostic indication and exploring additional tumor types like colorectal and non-small cell lung cancer.

• MODEYSO was approved for high-grade glioma, and ZEPZELCA expanded into frontline extensive stage small cell lung cancer.

• Early pipeline assets continue to progress, with collaborations in early breast cancer and neoadjuvant settings.

Regulatory and launch readiness

• Submission for frontline GEA was completed by end of February, leveraging real-time oncology review to expedite FDA evaluation.

• Expectation for approval by or before the August 25th PDUFA date, with potential for early NCCN guideline adoption.

• Launch preparations are advanced, leveraging existing relationships in BTC and GEA treatment communities and ongoing medical education.

• Confident in a strong launch, with revenue expected to be driven primarily by GEA uptake due to the larger patient population.

Clinical data insights and market potential

• Zanidatamab demonstrated superiority over Herceptin in frontline GEA, with clear benefit across PD-L1 positive and negative populations.

• Addition of tislelizumab (PD-1 inhibitor) showed significant survival benefit, with median overall survival exceeding 26 months versus less than 20 months for Herceptin chemo.

• Mechanistic differentiation of zanidatamab supports broad use with PD-1 inhibitors, and ongoing trials are evaluating combinations with other agents.

• U.S. market for HER2-positive GEA estimated at about 8,000 patients, with strong impetus for HER2 testing and rapid adoption expected.

• Peak sales estimate for zanidatamab remains at $2 billion-plus, with potential for upward revision as new indications and data mature.